Allinky Biopharma

Go to content

Main menu:

Allinky Biopharma is a start-up company with a proprietary technology platform that focuses its activities on the discovery and development of small molecules for the treatment of cancer and inflammatory diseases. The company was founded in 2009 by internationally renowned researchers in basic and clinical sciences who have a personal commitment to apply their research findings to the discovery of novel therapies.

Allinky aims to improve the treatment of prevalent pathologies and life-threatening diseases by addressing their molecular origins, and by following nature's strategy to control the excess activation of a given target protein (disease driver) using an innovative class of therapeutic agents: allosteric modulators.




News & Events
  • Plos One publishes latest results on Allinky's allosteric modulators of MAP Kinases
  • Allinky accepts invitation to participate in the 2017 fourteenth annual Anglonordic Life Science Conference in London.
  • Journal of Alzheimer's Disease publishes latest results on Allinky's protein-protein interaction inhibitos
  • The EU Eurostars Progam grants Allinky with a new project on Oncology
  • In March 2016 Allinky closes a fifth round of Seed Funding
  • Cell publishes latest results from Allinky's founder Dr. Torres Aleman
  • Allinky's CEO participates as speaker in the 3rd European Neurotech & Investing & Partnering Summit in Geneva
  • Allinky in the Spanish press
  • Allinky appoints Rob M. Elfont (Strategic Clinical Development LLC) member of the Board
  • In October 2014 Allinky closes a fourth round of Seed Funding
  • Allinky appoints Dr. L√≥pez-Figueroa (Bay City Capital) as member of the Board
  • In April 2013 Allinky closes a third round of Seed Funding

  •  Nature Reviews publishes latest results from Allinky's founder Dr. Torres-Aleman: "The many faces of insulin-like signalling in the brain." March 2012.
 
Back to content | Back to main menu